BioSpace News Archive

Galderma, the world’s largest independent dermatology company, announced that Maria Teresa “Tessa” Hilado will join its Advisory Committee, effective January 1, 2022.

Sino Biological, Inc. announced that it has launched a panel of research reagents for the newly identified Omicron variant of the SARS-COV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike protein.

Metrion Biosciences Limited, the specialist ion channel contract research and drug discovery company, announced it has expanded its capabilities and expertise through the addition of automated low volume liquid handling capability and 384-well electrophysiology and fluorescence-based high throughput screening assay systems.

METiS Therapeutics debuts with $86 million Series A financing to harness artificial intelligence and machine learning to redefine drug discovery and delivery and develop optimal therapies for patients with serious diseases.

CB Scientific. Inc. announced Shenzhen Pump Medical System Co., Ltd. has issued a formal Letter of Intent to manufacture the Company’s products targeting key Southeast Asia markets including China, Malaysia, Thailand, Indonesia, and Singapore.

SynDevRx, Inc. today announced a research collaboration with Australia’s Queensland University of Technology.

MiMedx Group, Inc., a transformational placental biologics company, will provide new details about near- and long-term growth opportunities for its multimodal placental tissue platform at ’s virtual Investor Day, which begins at 9:00 a.m. ET.

Medicago, today announce positive efficacy and safety results from the global Phase 3 placebo-controlled efficacy study of Medicago’s plant-based COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, conducted in over 24,000 subjects, adults 18 years and above, across six countries.

IDEAYA Biosciences, Inc. provided a clinical data update for the Phase 1/2 trial evaluating darovasertib and crizotinib synthetic lethal combination in metastatic uveal melanoma (MUM) patients.

Prelude Corporation announced the publication of SweDCIS randomized clinical trial data in the Special Issue : Updates on Breast Cancer edition of Cancers.